RTTNews | Sep 14, 2020 08:53AM EDT

08:53 Monday, September 14, 2020 (RTTNews.com) - Moleculin Biotech Inc. (MBRX) said Monday that it has contracted with an independent laboratory to test the antiviral activity of its WP1122 portfolio in a COVID-19 animal model.

The company contracted with an independent laboratory for in vivo testing of its drug candidate, WP1122 and another candidate from the same portfolio in development as a possible treatment for COVID-19. The final data may be available in December, the company said.

The company said it also plans to conduct other in vivo studies, intended to enable the company to file a complete Investigational New Drug application with the US Food and Drug Administration.

Moleculin said that, based on feedback from FDA, the company believes it may need to demonstrate activity in a COVID-19 animal model to successfully submit a request for IND status for WP1122.

In addition, the company also continues to contract with independent labs to conduct additional in vitro studies, which are currently under way.

Read the original article on RTTNews ( https://www.rttnews.com/3128297/moleculin-covid-19-in-vivo-testing-contracted-for-wp1122.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved